Quotient Sciences Quotient Sciences

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Viela Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Viela Bio Announces Positive Interim Results from a Phase 1b Study of VIB7734 in Patients with Cutaneous Lupus Erythematosus","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I"},{"orgOrder":0,"company":"Viela Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Viela Bio Announces Data Presentations at the 8Th Joint Actrims-Ectrims Meeting, Ms Virtual 2020","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"September 2020","url1":"","url2":"","graph1":"Immunology","graph2":"Approved"},{"orgOrder":0,"company":"Viela Bio","sponsor":"Horizon Therapeutics","pharmaFlowCategory":"D","amount":"$3,005.0 million","upfrontCash":"$3,005.0 million","newsHeadline":"Horizon Therapeutics to Acquire Viela Bio, Inc. to Significantly Expand Development Pipeline and Grow Rare Disease Medicine Portfolio","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"February 2021","url1":"","url2":"","graph1":"Immunology","graph2":"Approved"},{"orgOrder":0,"company":"Viela Bio","sponsor":"Horizon Therapeutics","pharmaFlowCategory":"D","amount":"$3,005.0 million","upfrontCash":"$3,005.0 million","newsHeadline":"Horizon Therapeutics Plc Completes Acquisition of Viela Bio, Inc.","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"March 2021","url1":"","url2":"","graph1":"Immunology","graph2":"Approved"},{"orgOrder":0,"company":"Viela Bio","sponsor":"Ventyx Biosciences","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Inflammatory Disease Biotech Ventyx Biosciences Files for A $100 Million IPO","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","url1":"","url2":"","graph1":"Immunology","graph2":"Phase I"}]

    Find Clinical Drug Pipeline Developments & Deals by Viela Bio

    Menu

    Viela Bio

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Forms

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Viela Bio

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Inflammatory Disease Biotech Ventyx Biosciences Files for A $100 Million IPO

              Details:

              VTX958, an oral, selective clinical-stage tyrosine kinase type 2 inhibitor that it believes has the potential to address a broad range of immune-mediated diseases, such as psoriasis, inflammatory bowel disease, psoriatic arthritis, and lupus.

              Lead Product(s): VTX958

              Therapeutic Area: Immunology Product Name: VTX958

              Highest Development Status: Phase I Product Type: Small molecule

              Recipient: Ventyx Biosciences

              Deal Size: $100.0 million Upfront Cash: Undisclosed

              Deal Type: Public Offering September 29, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Viela Bio

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Horizon Therapeutics Plc Completes Acquisition of Viela Bio, Inc.

              Details:

              Horizon Therapeutics gets UPLIZNA, first and only FDA-approved B-cell-depleting humanized monoclonal antibody for the treatment of neuromyelitis optica spectrum disorder.

              Lead Product(s): Inebilizumab

              Therapeutic Area: Immunology Product Name: Uplizna

              Highest Development Status: Approved Product Type: Large molecule

              Partner/Sponsor/Collaborator: Horizon Therapeutics

              Deal Size: $3,005.0 million Upfront Cash: $3,005.0 million

              Deal Type: Acquisition March 15, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Viela Bio

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Horizon Therapeutics to Acquire Viela Bio, Inc. to Significantly Expand Development Pipeline and Grow Rare Disease Medicine Portfolio

              Details:

              Horizon adds UPLIZNA® (inebilizumab-cdon) to its commercial rare disease medicine portfolio. The acquisition Adds deep, mid-stage biologics pipeline focused primarily on autoimmune and severe inflammatory diseases.

              Lead Product(s): Inebilizumab

              Therapeutic Area: Immunology Product Name: Uplizna

              Highest Development Status: Approved Product Type: Large molecule

              Partner/Sponsor/Collaborator: Horizon Therapeutics

              Deal Size: $3,005.0 million Upfront Cash: $3,005.0 million

              Deal Type: Acquisition February 01, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Viela Bio

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Viela Bio Announces Data Presentations at the 8Th Joint Actrims-Ectrims Meeting, Ms Virtual 2020

              Details:

              First poster will highlights study results in AQP4-IgG seronegative patients in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorder.

              Lead Product(s): Inebilizumab

              Therapeutic Area: Immunology Product Name: Uplizna

              Highest Development Status: Approved Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable September 03, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Viela Bio

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Viela Bio Announces Positive Interim Results from a Phase 1b Study of VIB7734 in Patients with Cutaneous Lupus Erythematosus

              Details:

              The interim findings indicated safety and tolerability comparable to placebo control across all cohorts, potent depletion of pDC both in peripheral blood and in inflamed CLE skin lesion biopsies in cohort 2, and dose-dependent reduction in CLASI after treatment with VIB7734.

              Lead Product(s): VIB7734

              Therapeutic Area: Immunology Product Name: Undisclosed

              Highest Development Status: Phase I Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable May 14, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
              Aspen API. More than just an API.
              Post Enquiry
              POST ENQUIRY